- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05539560
Association Between Smell Training and Quality of Life in Patients With Impaired Sense of Smell Following COVID-19 (SMELLT2022)
Association Between Olfactory Training and Quality of Life in Patients With Impaired Sense of Taste and Smell Following COVID-19
Aim: The aim is to investigate whether guided systematic olfactory training with essential oils to improve impaired sense of smell following COVID-19, can improve patients' quality of life.
Hypothesis: The impaired quality of life in patients with impaired sense of smell following COVID-19, can be significantly improved in patients performing olfactory training with essential oils, compared to patients performing olfactory training with placebo oils.
Study design: The study is a randomized clinical trial with an intervention group and a control group. The intervention group receive four essential oils with scents of orange, lavender, clove, and peppermint. Patients in the control group receive a fragrance kit, consisting of the same containers, but with fragrance-free oils added. Both groups are instructed to smell each of the four oils for 30 seconds in the morning and evening, over a three-month intervention period. Patients are given a diary in which to record their olfactory training. The nurse or medical student instructing the patients in the training and performing the smell and taste tests is blinded.
Study population: Patients referred to the Unit for Sense of Taste and Smell in the Department of Otorhinolaryngology Head & Neck and Audiology at Rigshospitalet.
Inclusion criteria:
- Impaired sense of taste and smell following COVID-19 > 3 months
- Hyposmia (15-30) or anosmia (<15) assessed by Sniffin' Sticks Olfactory Test for Threshold, Discrimination and Identification (TDI) performed in the Unit for Sense of Taste and Smell or medical assessment of parosmia based on medical history
- > 18 years of age
Exclusion criteria:
- Cause of hyposmia, anosmia or parosmia other than COVID-19
- Impaired sense of taste and smell >24 months
- Does not read or speak Danish
- Lack of compliance to perform daily olfactory training
Procedures:
- TDI-test: To assess patients' sense of smell, the TDI-test with Sniffin' Sticks is used, which is a validated tool with normative data.
- Taste test: To assess patients' sense of taste, taste sprays with the basic tastes are used.
Questionnaires:
- 'Taste and Smell Tool for Evaluation' is used to investigate quality of life related to impaired sense of taste and smell.
- 'Major Depression Inventory' (MDI) is used in the project to assess whether the patient is depressed and to make a possible assessment of the severity of depression.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vibeke Backer, Professor
- Phone Number: +45 35456033
- Email: nina.vibeke.backer@regionh.dk
Study Contact Backup
- Name: Ditte G Gertz Mogensen, PhD-student
- Phone Number: +45 35457508
- Email: ditte.gertz.mogensen@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Copenhagen University Hospital
-
Contact:
- Ditte Gertz Mogensen, PhD-student
- Phone Number: +45 35457508
- Email: ditte.gertz.mogensen@regionh.dk
-
Contact:
- Vibeke Backer, Professor
- Phone Number: +45 3545 6033
- Email: nina.vibeke.backer@regionh.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Olfactory dysfunction caused by COVID-1
- Hyposmia (15-30) or anosmia (<15) assessed by TDI test with Sniffin Sticks performed in the Unit for Sense of Taste and Smell or medical assessment of parosmia based on medical history
- > 18 years of age
Exclusion Criteria:
- Cause of hyposmia, anosmia or parosmia other than COVID-19
- Does not read or speak Danish
- Lack of compliance to perform daily olfactory training
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Olfactory training twice a day with essential oils
|
Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint.
The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
Other Names:
|
Placebo Comparator: Control group
Olfactory training twice a day with fragrance-free oils
|
Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group.
The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life
Time Frame: 3 months follow-up
|
Change in Quality of Life measured by the questionnaire Taste and Smell Tool for Evaluation.
The minimum score is 21 and the maximum score is 105.
A higher score means worse outcome (quality of life).
|
3 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Extended Sniffin' Sticks Test score
Time Frame: 3 months follow-up
|
Change in TDI score measured by Burghart Extended Sniffin' Sticks Test (TDI test).
The TDI test, consists of a threshold test, a discrimination test, and an identification test.
The results of the three subtests makes a total TDI score, where the minimum score is 1 and the maximum score is 48.
A score >30 indicates normal olfactory function, a score between 15-30 indicates hyposmia and a score <15 indicates anosmia in the form of severely impaired or complete loss of olfaction.
|
3 months follow-up
|
Change in Major Depression Inventory score (MDI)
Time Frame: 3 months follow-up
|
Change in MDI score measured by Major Depression Inventory.
The theoretical sum score ranges from 0 (no depression) to 50 (maximum depression).
|
3 months follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Vibeke G Backer, Professor, Rigshospitalet, Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-ENT-1-olfactory
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Olfactory training with essential oils
-
University of California, IrvineProcter and GambleTerminated
-
University Hospital, LilleRecruiting
-
Etablissement Public de Santé Barthélemy DurandRecruitingPsychiatric Disorder | Benzodiazepine WithdrawalFrance
-
Center Eugene MarquisTerminated
-
Özlem ÇağanCompletedAnxiety | Aromatherapy | Pain, LaborTurkey
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityEnrolling by invitationMalignant Solid Neoplasm | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III... and other conditionsUnited States
-
University of AlbertaTaiga BioActives Inc.WithdrawnUrinary Tract InfectionsCanada
-
Clinica Luganese MoncuccoCompletedBPSD (Behavioral and Psycological Symptoms of Dementia)Switzerland
-
Centre Francois BaclesseCompletedNausea and Vomiting | Aromatherapy | Essential Oil | Suportive CareFrance